Exchange: NASDAQ·Updated 07:55 PM EST

RADX News

News
all
press releases
GE HealthCare Wins Approval for MINItrace Magni Cyclotron in Europe
GE HealthCare secures CE Mark certification for MINItrace Magni and expands Copper-64 production capabilities, strengthening its PET imaging and theranostics portfolio.
Zacks
GE HealthCare Wins Approval for MINItrace Magni Cyclotron in Europe
GE HealthCare secures CE Mark certification for MINItrace Magni and expands Copper-64 production capabilities, strengthening its PET imaging and theranostics portfolio.
Zacks
More News
Wall Street analysts began coverage on top names, including a bullish rating on Radiopharm Theranostics. See more analyst ratings.read more...
Benzinga
Radiopharm Theranostics (NASDAQ:RADX) outlined progress across its radiopharmaceutical pipeline and highlighted near-term clinical catalysts during a presentation at the 30th Deutsche Bank Depositary Receipts Virtual Investor Conference. Chief Executive Officer Riccardo Canevari described the compa...
MarketBeat
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totaling...
MarketBeat
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was...
MarketBeat
Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the four analysts that are presently covering...
MarketBeat
(RTTNews) - Radiopharm Theranostics Ltd. (RADX) said Tuesday it has signed a supply agreement with Siemens Healthineers for RAD101, a novel imaging small molecule targeting fatty acid synthase (FASN) to diagnose suspected recurrent brain metastases from solid tumors...
Nasdaq News: Markets
Radiopharm Theranostics (NASDAQ:RADX) executives and clinical investigators highlighted new interim findings from the company's ongoing Phase IIb study of RAD101, a PET imaging tracer intended to...
MarketBeat
Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) have been given an average recommendation of "Buy" by the five analysts that are covering the firm...
MarketBeat
Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the recipient of a significant decline in short interest during the month of February. As of February 27th, there...
MarketBeat

Advertisement|Remove ads.